E-NEWS FROM THE NATIONAL VACCINE INFORMATION CENTER

Vienna, Virginia                                    http://www.909shot.com

* * * * * * * * * * * * * * * * * * * * * * *

UNTIED WAY/COMBINED FEDERAL CAMPAIGN

#9119

* * * * * * * * * * * * * * * * * * * * * * *

“Protecting the health and informed consent rights of children since 1982.” =============================================

FROM THE FEAT NEWS.

August 23, 2001                     Search  www.feat.org/search/news.asp

SCIENCE

·        Cure Autism Now Announces New Environmental Influences on Autism

Initiative

Six New Research Awards

1.   Comparison of ethylmercury developmental neurotoxic properties with an established model of methylmercury developmental neurotoxicity

2.   Double-blind placebo-controlled cross-over study of DMSA and lipoic acid for the treatment of children with regressive autism

3.   A comparative study evaluating the dose-responsiveness effects of methylmercury and thimerosal on select nervous, immune and enzyme parameters

4.   Evaluation of chelation effect on children with autism

5.   Role of cytokines in developmental neurotoxicit

6.   Effect of mercury on apoptosis of neuronal cells

 

·        Kids of Bipolar Parents May Not Face Higher Risk

 

 

Cure Autism Now Announces New Environmental Influences on Autism Initiative

Cure Autism Now is pleased to announce six new research awards as part of an Environmental Influences on Autism Initiative. These particular grants were made possible by a generous contribution from Sallie and Tom Bernard, and are the result of an RFP distributed to the scientific community to examine the possible metabolic, molecular, genetic or other response to mercury as it relates to autism.

Exposure to mercury, a potent neurotoxin, has shown to cause immune, sensory, neurological, motor and behavioral dysfunctions similar to traits defining or associated with autism. Although the FDA recently removed thimerosal from vaccines, the high number of anecdotal reports was compelling enough to Cure Autism Now to want to establish scientific data on whether and how mercury may play a role in causing autism, as well as how to treat its effects.

Among the diverse research projects that Cure Autism Now will be funding include projects focusing on molecular structure; chelation studies using DMSA and DMPS to determine this treatment’s efficacy; the comparative aspects of methyl vs. ethyl mercury; and animal and human therapeutic studies. Cure Autism Now assembled a special scientific advisory board with expertise in heavy metal toxicity who reviewed all proposals received. We express our sincere appreciation to them, and particularly to Chair David Baskin, M.D., for his time, dedication and integrity.

Elizabeth Tegley

Science Program Officer

Cure Autism Now

etegley@cureautismnow.org

 

Comparison of ethylmercury developmental neurotoxic properties with an

established model of methylmercury developmental neurotoxicity

Jay Charleston, Ph.D., Institute of Neurotoxicology and Neurological

Disorders

Relatively little information is known about the potential developmental neurotoxicity of ethylmercury (EtHg), the active ingredient of thimerosal, a bacteria static agent commonly used to preserve vaccines.  Vaccination of children following the recommended pediatrics schedule may result in exposure levels which may contribute to neurologic deficits. The lack of adequate information about the known neurotoxic potential of EtHg has forced the FDA to set exposure levels based on known developmental neurotoxic effects of methylmercury (MeHg). This assumption by the FDA assumes that MeHg and EtHg are equivalent. This hypothesis needs to be tested.

We are currently conducting a large study of the developmental consequence of very low levels of MeHg in a mouse model. This project is being funded by a grant from the United States Environmental Protection Agency (USEPA). Briefly, we are investigating subtle changes in specific brain sites using state-of-the-art stereological methods combined with histochemical and immunohistochemical staining techniques. We are investigating four exposure levels at four time points. These time points are selected to take advantage of unique temporally separated events in the developing mouse brain representing specific neural cell proliferation and migratory sequences. The endpoint is the quantification of neuron number in the cerebral cortex, cerebellum and midbrain structures.

The proposed experimental design will seek to replicate the above research model with EtHg exposure in place of MeHg exposure. This will allow us to determine the relative equivalency of the neurotoxic effects of these two compounds. The results will directly serve to assess if the FDA allowance of thimerosal in vaccine preparations based on MeHg exposure risk assessment is a reasonable decision.

Double-blind placebo-controlled cross-over study of DMSA and lipoic acid for

the treatment of children with regressive autism

Jane M. El-Dahr, M.D., Tulane University School of Medicine

The incidence of autism in the U.S. has increased over the past decade

at the same time that infants were exposed to organic mercury through the preservative thimerosal in childhood vaccines The many parallels between autism and mercury toxicity - individual susceptibility, delayed loss of skills, brain pathology, neuropsychiatric manifestations, autoimmunity directed against brain components - have led to the concern that regressive autism may represent a unique form of mercury poisoning. Anecdotal evidence suggests that symptoms of autism may improve with chelation. We propose to study the effect of treatment with the well-characterized chelating agent meso-2,3-dimercaptosuccnic acid (DMSA) combined with lipoic acid in young children with autism.

Hypothesis: Regressive autism, in some children, is the result of early exposure to mercury and symptoms can be diminished with removal of toxic metals. Aims: Estimate exposure to mercury in fetal and postnatal life in children with regressive autism; measure mercury and heavy metals present at baseline as well as released during treatment with urine, stool, and hair samples; quantitate anti-brain antibodies pre- and post-treatment; and determine the efficacy of this treatment to improve core autistic symptoms.  Design: Double-blind placebo-controlled cross-over with eight months in each arm. Forty children ages 2-5 years with DSM IV autism and a history of developmental regression will be enrolled. Standardized psychometric testing of intelligence, language, and behavior will be done at baseline, cross-over, and completion of study and rating scales of autistic behavior determined every two months.

A comparative study evaluating the dose-responsiveness effects of

methylmercury and thimerosal on select nervous, immune and enzyme parameters

Deborah Keil, Ph.D., Medical University of South Carolina

Infantile autism (IA) is a neurodevelopmental syndrome found in 1-5

cases of every 10,000 children with boys acquiring this syndrome 3-5 times more than girls. The spectrum of disorders of autism includes a range of impaired development of language and communication, unusual behaviors, and mental retardation. A diversity of pathophysiological effects also exist to include hyperserotoninemia, decreased T-cell proliferative function and activation, increased soluble IL-2 levels in serum, decreased CD8+ cells, decreased NK cells, development of anti-brain autoantibodies, decreased cerebellum volume and Purkinje cell number. Several studies indicate that the etiology of IA is multi-factorial and includes exposure to environmental chemicals. In particular, mercury exposure during infant and child development has been implicated in IA, especially in the case of vaccines containing mercury. Although mercury exposure from vaccines has been implicated in autism, this association !

!

has been criticized due to a lack of supportive experimental dose-response data. Thus, the proposed study will assess the possible role of methylmercury (MeHg) and thimerosal (TH) in contributing to the pathophysiology of IA using a mouse model to assess dose-responsive effects in cognitive and physiological parameters that encompass nervous, immune and enzyme pathways. This comparative approach will permit increased understanding of deficits due to MeHg or TH after acute exposure during early developmental stages and facilitate understanding of etiological causes of autism or other neurodevelopmental diseases. Furthermore, this study will also improve our understanding of the health effects attributed to different forms of mercury and contribute to the development of toxicological risk assessment models for detecting environmental contaminants that would adversely impact children’s health.

Evaluation of chelation effect on children with autism

Patricia Rosen, M.D., MPH, Texas Center for Autism Research and

Treatment

Vaccine injections have been blamed as a potential source of mercury exposure in early childhood. Based on the recommended childhood immunization schedule the cumulative amount of mercury given to a two-year-old child would be about 237.5 micrograms. Whether or not this could have resulted in an increase in the incidence of autism either through exposure to mercury or through an effect on the immune system is in question. Clinical similarities of patients with mercury poisoning to patients with autism as reported in ARC Research, has also caused concern. Although there is a significant safety margin incorporated into acceptable mercury exposure limits, some children could be exposed to a cumulative dose over the first 6 months of life that exceeds federal guidelines on methyl mercury. We propose to do a prospective, randomized double blind, cross over study that evaluates the effect of chelation therapy with DMPS on neurobehavioral functioning of children with autism. DM!

!

PS is an investigational drug that has been used in Europe and Russia for many years (since 1958) for the treatment of heavy metal poisoning. It has also been used in the United States on a compassionate use basis for heavy metal poisoning when other available medicines have either been ineffective or contraindicated. DMPS is very effective in removing mercury, lead and other heavy metals from humans but the question to be asked is will it help our children who have been diagnosed with autism.

Role of cytokines in developmental neurotoxicity

Ellen Silbergeld, Ph.D., University of Maryland School of Medicine

Methyl mercury (MeHg) is an environmental pollutant that causes

profound neurotoxicity and has been associated with autism. A major toxic effect associated MeHg exposure in humans is damage to the developing nervous system, involving inhibition of cell migration. This project will test the hypothesis that methyl mercury disrupts neurodevelopment through perturbing cytokine-directed neural migration, resulting in permanent structural alterations of the CNS and behavioral and cognitive dysfunction.  By defining the role of inflammatory cytokines in brain development, the results of this project may also have implications for understanding mechanisms by which maternal infections increase risks of autism and other perinatal brain disorders.

Effect of mercury on apoptosis of neuronal cells

Leman Yel, M.D., University of California, Irvine

Organic mercury compounds are known to be toxic mainly to the nervous

system. Recently, the similarities between the neurological findings in mercury exposure and autism have come to attention. It has been estimated that children are exposed to a quantity of mercury that exceeds the safety guidelines in the first two years of life through thimerosal (ethylmercury salicylate) in vaccines. And, a strong association between the administration of certain vaccinations and the onset of autistic manifestations has been noted. Autism is a multi-factorial disease in the pathogenesis of which genetic, immunological, and environmental factors play a role. Brain biopsies from autistic children show degeneration and a loss of neuronal cells without any evidence of inflammation that is consistent with an apoptotic (programmed cell death) process. Mercury accumulates in the mitochondria and disrupts cell energetics. It has been shown to induce apoptosis by causing mitochondrial dysfunc!

!

tion in lymphocytes. No study has been published on the apoptotic effect of mercury in the nervous system. We hypothesize that mercury induces apoptosis in neuronal cells and this effect is mainly via the mitochondrial pathway.  This might be more pronounced in children with autism because of genetic susceptibility. Thus, apoptosis due to mercury exposure may contribute to the pathogenesis of autism. Therefore, we intend to examine the effect of thimerosal on apoptosis induction and the signaling steps of mitochondrial pathway of apoptosis in neuronal cells. The results would clarify the effect of a mercury compound in neuronal cell death and degeneration, and provide a better understanding of the potential role of mercury exposure in the pathogenesis of autism.

 

News@909shot.com is a free service of the National Vaccine Information

Center and is supported through membership donations.  Learn more about vaccines, diseases and how to protect your informed

consent rights http://www.909shot.com

Become a member and support NVIC’s work  https://www.909shot.com/order.htm

To sign up for a free e-mail subscription http://www.909shot.com/emaillist.htm

To unsubscribe from this list, send an email to news-request@909shot.com and type UNSUBSCRIBE in the body of the email.

NVIC is funded through individual membership donations and does not receive government funding. Barbara Loe Fisher, President and Co-founder.

NOTE: This is not an interactive e-mail list. Please do not respond to messages.

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.